-
1
-
-
70349233050
-
Cancer immunotherapy
-
COI: 1:CAS:528:DC%2BD1MXptlKnsbs%3D, PID: 19650714
-
Baxevanis CN, Perez SA, Papamichail M (2009) Cancer immunotherapy. Crit Rev Clin Lab Sci 46(4):167–189. doi:10.1080/10408360902937809
-
(2009)
Crit Rev Clin Lab Sci
, vol.46
, Issue.4
, pp. 167-189
-
-
Baxevanis, C.N.1
Perez, S.A.2
Papamichail, M.3
-
2
-
-
78650919399
-
Translating tumor antigens into cancer vaccines
-
COI: 1:CAS:528:DC%2BC3MXpslWntA%3D%3D, PID: 21048000
-
Buonaguro L, Petrizzo A, Tornesello ML, Buonaguro FM (2011) Translating tumor antigens into cancer vaccines. Clin Vaccine Immunol 18(1):23–34. doi:10.1128/CVI.00286-10
-
(2011)
Clin Vaccine Immunol
, vol.18
, Issue.1
, pp. 23-34
-
-
Buonaguro, L.1
Petrizzo, A.2
Tornesello, M.L.3
Buonaguro, F.M.4
-
3
-
-
84865694926
-
New anticancer immunotherapies
-
COI: 1:CAS:528:DC%2BC38Xht1aks7%2FF, PID: 22753700
-
Franks HA, Wang Q, Patel PM (2012) New anticancer immunotherapies. Anticancer Res 32(7):2439–2453
-
(2012)
Anticancer Res
, vol.32
, Issue.7
, pp. 2439-2453
-
-
Franks, H.A.1
Wang, Q.2
Patel, P.M.3
-
4
-
-
79957709717
-
Vaccines for the treatment of non-small cell lung cancer: investigational approaches and clinical experience
-
PID: 21474197
-
Mellstedt H, Vansteenkiste J, Thatcher N (2011) Vaccines for the treatment of non-small cell lung cancer: investigational approaches and clinical experience. Lung Cancer 73(1):11–17. doi:10.1016/j.lungcan.2011.02.023
-
(2011)
Lung Cancer
, vol.73
, Issue.1
, pp. 11-17
-
-
Mellstedt, H.1
Vansteenkiste, J.2
Thatcher, N.3
-
5
-
-
71949118684
-
Peptide-based anticancer vaccines: recent advances and future perspectives
-
COI: 1:CAS:528:DC%2BC3cXhsVSmsbY%3D, PID: 19929787
-
Mocellin S, Pilati P, Nitti D (2009) Peptide-based anticancer vaccines: recent advances and future perspectives. Curr Med Chem 16(36):4779–4796
-
(2009)
Curr Med Chem
, vol.16
, Issue.36
, pp. 4779-4796
-
-
Mocellin, S.1
Pilati, P.2
Nitti, D.3
-
6
-
-
0028298850
-
Tumour antigens. A new look for the 1990s
-
COI: 1:STN:280:DyaK2c3lsFSjug%3D%3D, PID: 8018207
-
Pardoll DM (1994) Tumour antigens. A new look for the 1990s. Nature 369(6479):357. doi:10.1038/369357a0
-
(1994)
Nature
, vol.369
, Issue.6479
, pp. 357
-
-
Pardoll, D.M.1
-
7
-
-
0029924107
-
Human tumor antigens recognized by T lymphocytes
-
COI: 1:CAS:528:DyaK28XhvV2rur8%3D, PID: 8642276
-
Boon T, van der Bruggen P (1996) Human tumor antigens recognized by T lymphocytes. J Exp Med 183(3):725–729
-
(1996)
J Exp Med
, vol.183
, Issue.3
, pp. 725-729
-
-
Boon, T.1
van der Bruggen, P.2
-
8
-
-
0027173861
-
Identification of peptide sequences that potentially trigger HLA-A2.1-restricted cytotoxic T lymphocytes
-
COI: 1:CAS:528:DyaK3sXkvFeit7o%3D, PID: 7684681
-
Nijman HW, Houbiers JG, Vierboom MP, van der Burg SH, Drijfhout JW, DAmaro J, Kenemans P, Melief CJ, Kast WM (1993) Identification of peptide sequences that potentially trigger HLA-A2.1-restricted cytotoxic T lymphocytes. Eur J Immunol 23(6):1215–1219. doi:10.1002/eji.1830230603
-
(1993)
Eur J Immunol
, vol.23
, Issue.6
, pp. 1215-1219
-
-
Nijman, H.W.1
Houbiers, J.G.2
Vierboom, M.P.3
van der Burg, S.H.4
Drijfhout, J.W.5
DAmaro, J.6
Kenemans, P.7
Melief, C.J.8
Kast, W.M.9
-
9
-
-
84867304928
-
Transcriptional activation and cell cycle block are the keys for 5-fluorouracil induced up-regulation of human thymidylate synthase expression
-
COI: 1:CAS:528:DC%2BC38XhsFCku73I, PID: 23056627
-
Ligabue A, Marverti G, Liebl U, Myllykallio H (2012) Transcriptional activation and cell cycle block are the keys for 5-fluorouracil induced up-regulation of human thymidylate synthase expression. Plos One 7(10):e47318. doi:10.1371/journal.pone.0047318
-
(2012)
Plos One
, vol.7
, Issue.10
, pp. e47318
-
-
Ligabue, A.1
Marverti, G.2
Liebl, U.3
Myllykallio, H.4
-
10
-
-
23244464739
-
Thymidylate synthase: a critical target in cancer therapy?
-
COI: 1:CAS:528:DC%2BD2cXltl2nu7Y%3D, PID: 15353299
-
Rustum YM (2004) Thymidylate synthase: a critical target in cancer therapy? Front Biosci 9:2467–2473
-
(2004)
Front Biosci
, vol.9
, pp. 2467-2473
-
-
Rustum, Y.M.1
-
11
-
-
0028265392
-
New targets for pyrimidine antimetabolites in the treatment of solid tumours. 1: thymidylate synthase
-
PID: 7518280
-
van der Wilt CL, Peters GJ (1994) New targets for pyrimidine antimetabolites in the treatment of solid tumours. 1: thymidylate synthase. Pharm World Sci 16(2):84–103
-
(1994)
Pharm World Sci
, vol.16
, Issue.2
, pp. 84-103
-
-
van der Wilt, C.L.1
Peters, G.J.2
-
12
-
-
26944455210
-
5-fluorouracil-based chemotherapy enhances the antitumor activity of a thymidylate synthase-directed polyepitopic peptide vaccine
-
COI: 1:CAS:528:DC%2BD2MXhtVyrtb%2FP, PID: 16204693
-
Correale P, Del Vecchio MT, Di Genova G, Savellini GG, La Placa M, Terrosi C, Vestri M, Urso R, Lemonnier F, Aquino A, Bonmassar E, Giorgi G, Francini G, Cusi MG (2005) 5-fluorouracil-based chemotherapy enhances the antitumor activity of a thymidylate synthase-directed polyepitopic peptide vaccine. J Natl Cancer Inst 97(19):1437–1445. doi:10.1093/jnci/dji188
-
(2005)
J Natl Cancer Inst
, vol.97
, Issue.19
, pp. 1437-1445
-
-
Correale, P.1
Del Vecchio, M.T.2
Di Genova, G.3
Savellini, G.G.4
La Placa, M.5
Terrosi, C.6
Vestri, M.7
Urso, R.8
Lemonnier, F.9
Aquino, A.10
Bonmassar, E.11
Giorgi, G.12
Francini, G.13
Cusi, M.G.14
-
13
-
-
0034783323
-
In vitro generation of cytotoxic T lymphocytes against HLA-A2.1-restricted peptides derived from human thymidylate synthase
-
COI: 1:CAS:528:DC%2BD3MXotlygtbk%3D, PID: 11760216
-
Correale P, Sabatino M, Cusi MG, Micheli L, Nencini C, Pozzessere D, Petrioli R, Aquino A, De Vecchis L, Turriziani M, Prete SP, Sanguedolce R, Rausa L, Giorgi G, Francini G (2001) In vitro generation of cytotoxic T lymphocytes against HLA-A2.1-restricted peptides derived from human thymidylate synthase. J Chemother 13(5):519–526. doi:10.1179/joc.2001.13.5.519
-
(2001)
J Chemother
, vol.13
, Issue.5
, pp. 519-526
-
-
Correale, P.1
Sabatino, M.2
Cusi, M.G.3
Micheli, L.4
Nencini, C.5
Pozzessere, D.6
Petrioli, R.7
Aquino, A.8
De, V.L.9
Turriziani, M.10
Prete, S.P.11
Sanguedolce, R.12
Rausa, L.13
Giorgi, G.14
Francini, G.15
-
14
-
-
44949096473
-
Chemotherapeutic drugs may be used to enhance the killing efficacy of human tumor antigen peptide-specific CTLs
-
COI: 1:CAS:528:DC%2BD1cXjt1Cju7g%3D, PID: 18481383
-
Correale P, Del Vecchio MT, La Placa M, Montagnani F, Di Genova G, Savellini GG, Terrosi C, Mannucci S, Giorgi G, Francini G, Cusi MG (2008) Chemotherapeutic drugs may be used to enhance the killing efficacy of human tumor antigen peptide-specific CTLs. J Immunother 31(2):132–147. doi:10.1097/CJI.0b013e31815b69c8
-
(2008)
J Immunother
, vol.31
, Issue.2
, pp. 132-147
-
-
Correale, P.1
Del Vecchio, M.T.2
La Placa, M.3
Montagnani, F.4
Di Genova, G.5
Savellini, G.G.6
Terrosi, C.7
Mannucci, S.8
Giorgi, G.9
Francini, G.10
Cusi, M.G.11
-
15
-
-
0035049617
-
Recruitment of dendritic cells and enhanced antigen-specific immune reactivity in cancer patients treated with hr-GM-CSF (Molgramostim) and hr-IL-2. Results from a phase Ib clinical trial
-
COI: 1:CAS:528:DC%2BD3MXislGhtbs%3D, PID: 11313178
-
Correale P, Campoccia G, Tsang KY, Micheli L, Cusi MG, Sabatino M, Bruni G, Sestini S, Petrioli R, Pozzessere D, Marsili S, Fanetti G, Giorgi G, Francini G (2001) Recruitment of dendritic cells and enhanced antigen-specific immune reactivity in cancer patients treated with hr-GM-CSF (Molgramostim) and hr-IL-2. Results from a phase Ib clinical trial. Eur J Cancer 37(7):892–902
-
(2001)
Eur J Cancer
, vol.37
, Issue.7
, pp. 892-902
-
-
Correale, P.1
Campoccia, G.2
Tsang, K.Y.3
Micheli, L.4
Cusi, M.G.5
Sabatino, M.6
Bruni, G.7
Sestini, S.8
Petrioli, R.9
Pozzessere, D.10
Marsili, S.11
Fanetti, G.12
Giorgi, G.13
Francini, G.14
-
16
-
-
23244464772
-
Dendritic cell-mediated cross-presentation of antigens derived from colon carcinoma cells exposed to a highly cytotoxic multidrug regimen with gemcitabine, oxaliplatin, 5-fluorouracil, and leucovorin, elicits a powerful human antigen-specific CTL response with antitumor activity in vitro
-
COI: 1:CAS:528:DC%2BD2MXlvFSjsbo%3D, PID: 16002679
-
Correale P, Cusi MG, Del Vecchio MT, Aquino A, Prete SP, Tsang KY, Micheli L, Nencini C, La Placa M, Montagnani F, Terrosi C, Caraglia M, Formica V, Giorgi G, Bonmassar E, Francini G (2005) Dendritic cell-mediated cross-presentation of antigens derived from colon carcinoma cells exposed to a highly cytotoxic multidrug regimen with gemcitabine, oxaliplatin, 5-fluorouracil, and leucovorin, elicits a powerful human antigen-specific CTL response with antitumor activity in vitro. J Immunol 175(2):820–828
-
(2005)
J Immunol
, vol.175
, Issue.2
, pp. 820-828
-
-
Correale, P.1
Cusi, M.G.2
Del Vecchio, M.T.3
Aquino, A.4
Prete, S.P.5
Tsang, K.Y.6
Micheli, L.7
Nencini, C.8
La Placa, M.9
Montagnani, F.10
Terrosi, C.11
Caraglia, M.12
Formica, V.13
Giorgi, G.14
Bonmassar, E.15
Francini, G.16
-
17
-
-
0036839142
-
High-affinity HLA-A(*)02.01 peptides from parathyroid hormone-related protein generate in vitro and in vivo antitumor CTL response without autoimmune side effects
-
PID: 12391194
-
Francini G, Scardino A, Kosmatopoulos K, Lemonnier FA, Campoccia G, Sabatino M, Pozzessere D, Petrioli R, Lozzi L, Neri P, Fanetti G, Cusi MG, Correale P (2002) High-affinity HLA-A(*)02.01 peptides from parathyroid hormone-related protein generate in vitro and in vivo antitumor CTL response without autoimmune side effects. J Immunol 169(9):4840–4849
-
(2002)
J Immunol
, vol.169
, Issue.9
, pp. 4840-4849
-
-
Francini, G.1
Scardino, A.2
Kosmatopoulos, K.3
Lemonnier, F.A.4
Campoccia, G.5
Sabatino, M.6
Pozzessere, D.7
Petrioli, R.8
Lozzi, L.9
Neri, P.10
Fanetti, G.11
Cusi, M.G.12
Correale, P.13
-
18
-
-
33644789357
-
Chemo-immunotherapy of metastatic colorectal carcinoma with gemcitabine plus FOLFOX 4 followed by subcutaneous granulocyte macrophage colony-stimulating factor and interleukin-2 induces strong immunologic and antitumor activity in metastatic colon cancer patients
-
COI: 1:CAS:528:DC%2BD28XktVCguw%3D%3D, PID: 16061910
-
Correale P, Cusi MG, Tsang KY, Del Vecchio MT, Marsili S, Placa ML, Intrivici C, Aquino A, Micheli L, Nencini C, Ferrari F, Giorgi G, Bonmassar E, Francini G (2005) Chemo-immunotherapy of metastatic colorectal carcinoma with gemcitabine plus FOLFOX 4 followed by subcutaneous granulocyte macrophage colony-stimulating factor and interleukin-2 induces strong immunologic and antitumor activity in metastatic colon cancer patients. J Clin Oncol 23(35):8950–8958. doi:10.1200/JCO.2005.12.147
-
(2005)
J Clin Oncol
, vol.23
, Issue.35
, pp. 8950-8958
-
-
Correale, P.1
Cusi, M.G.2
Tsang, K.Y.3
Del Vecchio, M.T.4
Marsili, S.5
Placa, M.L.6
Intrivici, C.7
Aquino, A.8
Micheli, L.9
Nencini, C.10
Ferrari, F.11
Giorgi, G.12
Bonmassar, E.13
Francini, G.14
-
19
-
-
48249096809
-
Immunity feedback and clinical outcome in colon cancer patients undergoing chemoimmunotherapy with gemcitabine + FOLFOX followed by subcutaneous granulocyte macrophage colony-stimulating factor and aldesleukin (GOLFIG-1 Trial)
-
COI: 1:CAS:528:DC%2BD1cXnvFyksro%3D, PID: 18593999
-
Correale P, Tagliaferri P, Fioravanti A, Del Vecchio MT, Remondo C, Montagnani F, Rotundo MS, Ginanneschi C, Martellucci I, Francini E, Cusi MG, Tassone P, Francini G (2008) Immunity feedback and clinical outcome in colon cancer patients undergoing chemoimmunotherapy with gemcitabine + FOLFOX followed by subcutaneous granulocyte macrophage colony-stimulating factor and aldesleukin (GOLFIG-1 Trial). Clin Cancer Res 14(13):4192–4199. doi:10.1158/1078-0432.CCR-07-5278
-
(2008)
Clin Cancer Res
, vol.14
, Issue.13
, pp. 4192-4199
-
-
Correale, P.1
Tagliaferri, P.2
Fioravanti, A.3
Del Vecchio, M.T.4
Remondo, C.5
Montagnani, F.6
Rotundo, M.S.7
Ginanneschi, C.8
Martellucci, I.9
Francini, E.10
Cusi, M.G.11
Tassone, P.12
Francini, G.13
-
20
-
-
0037379110
-
Multidisciplinary utilization of dimethyl sulfoxide: pharmacological, cellular, and molecular aspects
-
COI: 1:CAS:528:DC%2BD3sXit12gur0%3D, PID: 12663039
-
Santos NC, Figueira-Coelho J, Martins-Silva J, Saldanha C (2003) Multidisciplinary utilization of dimethyl sulfoxide: pharmacological, cellular, and molecular aspects. Biochem Pharmacol 65(7):1035–1041
-
(2003)
Biochem Pharmacol
, vol.65
, Issue.7
, pp. 1035-1041
-
-
Santos, N.C.1
Figueira-Coelho, J.2
Martins-Silva, J.3
Saldanha, C.4
-
21
-
-
0042914645
-
Modified fibonacci search
-
PID: 12915613
-
Omura GA (2003) Modified fibonacci search. J Clin Oncol 21(16):3177. doi:10.1200/JCO.2003.99.058
-
(2003)
J Clin Oncol
, vol.21
, Issue.16
, pp. 3177
-
-
Omura, G.A.1
-
22
-
-
84861235490
-
Immune-modulating effects of the newest cetuximab-based chemoimmunotherapy regimen in advanced colorectal cancer patients
-
COI: 1:CAS:528:DC%2BC38Xnt1elt7g%3D, PID: 22576349
-
Botta C, Bestoso E, Apollinari S, Cusi MG, Pastina P, Abbruzzese A, Sperlongano P, Misso G, Caraglia M, Tassone P, Tagliaferri P, Correale P (2012) Immune-modulating effects of the newest cetuximab-based chemoimmunotherapy regimen in advanced colorectal cancer patients. J Immunother 35(5):440–447. doi:10.1097/CJI.0b013e31825943aa
-
(2012)
J Immunother
, vol.35
, Issue.5
, pp. 440-447
-
-
Botta, C.1
Bestoso, E.2
Apollinari, S.3
Cusi, M.G.4
Pastina, P.5
Abbruzzese, A.6
Sperlongano, P.7
Misso, G.8
Caraglia, M.9
Tassone, P.10
Tagliaferri, P.11
Correale, P.12
-
23
-
-
0014385954
-
A one-stage procedure for isolation of granulocytes and lymphocytes from human blood. General sedimentation properties of white blood cells in a 1g gravity field
-
COI: 1:STN:280:DyaF1M7gtFKrtw%3D%3D
-
Boyum A (1968) A one-stage procedure for isolation of granulocytes and lymphocytes from human blood. General sedimentation properties of white blood cells in a 1g gravity field. Scand J Clin Lab Investig Suppl 97:51–76
-
(1968)
Scand J Clin Lab Investig Suppl
, vol.97
, pp. 51-76
-
-
Boyum, A.1
-
24
-
-
0021020342
-
A solid-phase enzyme-linked immunospot (ELISPOT) assay for enumeration of specific antibody-secreting cells
-
COI: 1:STN:280:DyaL2c%2FovFSgtA%3D%3D, PID: 6361139
-
Czerkinsky CC, Nilsson LA, Nygren H, Ouchterlony O, Tarkowski A (1983) A solid-phase enzyme-linked immunospot (ELISPOT) assay for enumeration of specific antibody-secreting cells. J Immunol Methods 65(1–2):109–121
-
(1983)
J Immunol Methods
, vol.65
, Issue.1-2
, pp. 109-121
-
-
Czerkinsky, C.C.1
Nilsson, L.A.2
Nygren, H.3
Ouchterlony, O.4
Tarkowski, A.5
-
25
-
-
77955551910
-
Response definition criteria for ELISPOT assays revisited
-
COI: 1:STN:280:DC%2BC3cnps1Gmtw%3D%3D
-
Moodie Z, Price L, Gouttefangeas C, Mander A, Janetzki S, Lower M, Welters MJ, Ottensmeier C, van der Burg SH, Britten CM (2010) Response definition criteria for ELISPOT assays revisited. Cancer Immunol Immun 59(10):1489–1501. doi:10.1007/s00262-010-0875-4
-
(2010)
Cancer Immunol Immun
, vol.59
, Issue.10
, pp. 1489-1501
-
-
Moodie, Z.1
Price, L.2
Gouttefangeas, C.3
Mander, A.4
Janetzki, S.5
Lower, M.6
Welters, M.J.7
Ottensmeier, C.8
van der Burg, S.H.9
Britten, C.M.10
-
26
-
-
84880916286
-
Novel adenoviral vector induces T-cell responses despite anti-adenoviral neutralizing antibodies in colorectal cancer patients
-
COI: 1:CAS:528:DC%2BC3sXht1Crsb7P
-
Morse MA, Chaudhry A, Gabitzsch ES, Hobeika AC, Osada T, Clay TM, Amalfitano A, Burnett BK, Devi GR, Hsu DS, Xu Y, Balcaitis S, Dua R, Nguyen S, Balint JP Jr, Jones FR, Lyerly HK (2013) Novel adenoviral vector induces T-cell responses despite anti-adenoviral neutralizing antibodies in colorectal cancer patients. Cancer Immunol Immun 62(8):1293–1301. doi:10.1007/s00262-013-1400-3
-
(2013)
Cancer Immunol Immun
, vol.62
, Issue.8
, pp. 1293-1301
-
-
Morse, M.A.1
Chaudhry, A.2
Gabitzsch, E.S.3
Hobeika, A.C.4
Osada, T.5
Clay, T.M.6
Amalfitano, A.7
Burnett, B.K.8
Devi, G.R.9
Hsu, D.S.10
Xu, Y.11
Balcaitis, S.12
Dua, R.13
Nguyen, S.14
Balint, J.P.15
Jones, F.R.16
Lyerly, H.K.17
-
27
-
-
0030918409
-
Validation of the EORTC QLQ-C30 quality of life questionnaire through combined qualitative and quantitative assessment of patient-observer agreement
-
COI: 1:STN:280:DyaK2szit1KisQ%3D%3D, PID: 9179103
-
Groenvold M, Klee MC, Sprangers MA, Aaronson NK (1997) Validation of the EORTC QLQ-C30 quality of life questionnaire through combined qualitative and quantitative assessment of patient-observer agreement. J Clin Epidemiol 50(4):441–450
-
(1997)
J Clin Epidemiol
, vol.50
, Issue.4
, pp. 441-450
-
-
Groenvold, M.1
Klee, M.C.2
Sprangers, M.A.3
Aaronson, N.K.4
-
28
-
-
79959201922
-
Myeloperoxidase: the yin and yang in tumour progression
-
COI: 1:CAS:528:DC%2BC3MXot1Oqtbk%3D, PID: 21699016
-
Mika D, Guruvayoorappan C (2011) Myeloperoxidase: the yin and yang in tumour progression. J Exp Ther Oncol 9(2):93–100
-
(2011)
J Exp Ther Oncol
, vol.9
, Issue.2
, pp. 93-100
-
-
Mika, D.1
Guruvayoorappan, C.2
-
29
-
-
77950346282
-
Immunity, inflammation, and cancer
-
COI: 1:CAS:528:DC%2BC3cXlsVSgu7g%3D, PID: 20303878
-
Grivennikov SI, Greten FR, Karin M (2010) Immunity, inflammation, and cancer. Cell 140(6):883–899. doi:10.1016/j.cell.2010.01.025
-
(2010)
Cell
, vol.140
, Issue.6
, pp. 883-899
-
-
Grivennikov, S.I.1
Greten, F.R.2
Karin, M.3
-
30
-
-
79960657821
-
Autoimmunity associated with immunotherapy of cancer
-
COI: 1:CAS:528:DC%2BC3MXpslyhtbg%3D, PID: 21531979
-
Amos SM, Duong CP, Westwood JA, Ritchie DS, Junghans RP, Darcy PK, Kershaw MH (2011) Autoimmunity associated with immunotherapy of cancer. Blood 118(3):499–509. doi:10.1182/blood-2011-01-325266
-
(2011)
Blood
, vol.118
, Issue.3
, pp. 499-509
-
-
Amos, S.M.1
Duong, C.P.2
Westwood, J.A.3
Ritchie, D.S.4
Junghans, R.P.5
Darcy, P.K.6
Kershaw, M.H.7
-
31
-
-
84874921468
-
Heat shock proteins, autoimmunity, and cancer treatment
-
PID: 23056925
-
Calderwood SK, Stevenson MA, Murshid A (2012) Heat shock proteins, autoimmunity, and cancer treatment. Autoimmune Dis 2012:486069. doi:10.1155/2012/486069
-
(2012)
Autoimmune Dis
, vol.2012
, pp. 486069
-
-
Calderwood, S.K.1
Stevenson, M.A.2
Murshid, A.3
-
32
-
-
84865552100
-
Immuno-oncology: understanding the function and dysfunction of the immune system in cancer
-
PID: 22918931
-
Finn OJ (2012) Immuno-oncology: understanding the function and dysfunction of the immune system in cancer. Ann Oncol 23(Suppl 8):viii6–viii9. doi:10.1093/annonc/mds256
-
(2012)
Ann Oncol
, vol.23
, pp. viii6-viii9
-
-
Finn, O.J.1
-
33
-
-
80052981497
-
Cancer vaccines inducing antibody production: more pros than cons
-
COI: 1:CAS:528:DC%2BC3MXhtFOju7vP, PID: 21919618
-
Jensen-Jarolim E, Singer J (2011) Cancer vaccines inducing antibody production: more pros than cons. Expert Rev Vaccines 10(9):1281–1289. doi:10.1586/erv.11.105
-
(2011)
Expert Rev Vaccines
, vol.10
, Issue.9
, pp. 1281-1289
-
-
Jensen-Jarolim, E.1
Singer, J.2
-
34
-
-
47949096781
-
Cancer-related inflammation
-
COI: 1:CAS:528:DC%2BD1cXovV2mtbg%3D, PID: 18650914
-
Mantovani A, Allavena P, Sica A, Balkwill F (2008) Cancer-related inflammation. Nature 454(7203):436–444. doi:10.1038/nature07205
-
(2008)
Nature
, vol.454
, Issue.7203
, pp. 436-444
-
-
Mantovani, A.1
Allavena, P.2
Sica, A.3
Balkwill, F.4
-
35
-
-
84873131533
-
Changes in the local tumor microenvironment in recurrent cancers may explain the failure of vaccines after surgery
-
COI: 1:CAS:528:DC%2BC3sXislKru70%3D, PID: 23271806
-
Predina J, Eruslanov E, Judy B, Kapoor V, Cheng G, Wang LC, Sun J, Moon EK, Fridlender ZG, Albelda S, Singhal S (2013) Changes in the local tumor microenvironment in recurrent cancers may explain the failure of vaccines after surgery. Proc Natl Acad Sci USA 110(5):E415–E424. doi:10.1073/pnas.1211850110
-
(2013)
Proc Natl Acad Sci USA
, vol.110
, Issue.5
, pp. E415-E424
-
-
Predina, J.1
Eruslanov, E.2
Judy, B.3
Kapoor, V.4
Cheng, G.5
Wang, L.C.6
Sun, J.7
Moon, E.K.8
Fridlender, Z.G.9
Albelda, S.10
Singhal, S.11
-
36
-
-
84892740595
-
Immunomodulatory effects in a phase II study of lenalidomide combined with cetuximab in refractory KRAS-mutant metastatic colorectal cancer patients
-
COI: 1:CAS:528:DC%2BC3sXhslyls7nF, PID: 24244687
-
Gandhi AK, Shi T, Li M, Jungnelius U, Romano A, Tabernero J, Siena S, Schafer PH, Chopra R (2013) Immunomodulatory effects in a phase II study of lenalidomide combined with cetuximab in refractory KRAS-mutant metastatic colorectal cancer patients. Plos One 8(11):e80437. doi:10.1371/journal.pone.0080437
-
(2013)
Plos One
, vol.8
, Issue.11
, pp. e80437
-
-
Gandhi, A.K.1
Shi, T.2
Li, M.3
Jungnelius, U.4
Romano, A.5
Tabernero, J.6
Siena, S.7
Schafer, P.H.8
Chopra, R.9
-
37
-
-
84879182577
-
Systemic inflammatory status at baseline predicts bevacizumab benefit in advanced non-small cell lung cancer patients
-
COI: 1:CAS:528:DC%2BC2cXjvFOrtb0%3D, PID: 23760488
-
Botta C, Barbieri V, Ciliberto D, Rossi A, Rocco D, Addeo R, Staropoli N, Pastina P, Marvaso G, Martellucci I, Guglielmo A, Pirtoli L, Sperlongano P, Gridelli C, Caraglia M, Tassone P, Tagliaferri P, Correale P (2013) Systemic inflammatory status at baseline predicts bevacizumab benefit in advanced non-small cell lung cancer patients. Cancer Biol Ther 14(6):469–475. doi:10.4161/cbt.24425
-
(2013)
Cancer Biol Ther
, vol.14
, Issue.6
, pp. 469-475
-
-
Botta, C.1
Barbieri, V.2
Ciliberto, D.3
Rossi, A.4
Rocco, D.5
Addeo, R.6
Staropoli, N.7
Pastina, P.8
Marvaso, G.9
Martellucci, I.10
Guglielmo, A.11
Pirtoli, L.12
Sperlongano, P.13
Gridelli, C.14
Caraglia, M.15
Tassone, P.16
Tagliaferri, P.17
Correale, P.18
-
38
-
-
84875280049
-
Advance lung cancer inflammation index (ALI) at diagnosis is a prognostic marker in patients with metastatic non-small cell lung cancer (NSCLC): a retrospective review
-
PID: 23530866
-
Jafri SH, Shi R, Mills G (2013) Advance lung cancer inflammation index (ALI) at diagnosis is a prognostic marker in patients with metastatic non-small cell lung cancer (NSCLC): a retrospective review. BMC Cancer 13:158. doi:10.1186/1471-2407-13-158
-
(2013)
BMC Cancer
, vol.13
, pp. 158
-
-
Jafri, S.H.1
Shi, R.2
Mills, G.3
-
39
-
-
84905164478
-
Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis
-
PID: 24875653
-
Templeton AJ, McNamara MG, Seruga B, Vera-Badillo FE, Aneja P, Ocana A, Leibowitz-Amit R, Sonpavde G, Knox JJ, Tran B, Tannock IF, Amir E (2014) Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst 106(6):dju124. doi:10.1093/jnci/dju124
-
(2014)
J Natl Cancer Inst
, vol.106
, Issue.6
, pp. dju124
-
-
Templeton, A.J.1
McNamara, M.G.2
Seruga, B.3
Vera-Badillo, F.E.4
Aneja, P.5
Ocana, A.6
Leibowitz-Amit, R.7
Sonpavde, G.8
Knox, J.J.9
Tran, B.10
Tannock, I.F.11
Amir, E.12
-
40
-
-
84890897595
-
Gemcitabine, oxaliplatin, levofolinate, 5-fluorouracil, granulocyte-macrophage colony-stimulating factor, and interleukin-2 (GOLFIG) versus FOLFOX chemotherapy in metastatic colorectal cancer patients: the GOLFIG-2 multicentric open-label randomized phase III trial
-
COI: 1:CAS:528:DC%2BC3sXhvFSru77F, PID: 24316553
-
Correale P, Botta C, Rotundo MS, Guglielmo A, Conca R, Licchetta A, Pastina P, Bestoso E, Ciliberto D, Cusi MG, Fioravanti A, Guidelli GM, Bianco MT, Misso G, Martino E, Caraglia M, Tassone P, Mini E, Mantovani G, Ridolfi R, Pirtoli L, Tagliaferri P (2014) Gemcitabine, oxaliplatin, levofolinate, 5-fluorouracil, granulocyte-macrophage colony-stimulating factor, and interleukin-2 (GOLFIG) versus FOLFOX chemotherapy in metastatic colorectal cancer patients: the GOLFIG-2 multicentric open-label randomized phase III trial. J Immunother 37(1):26–35. doi:10.1097/CJI.0000000000000004
-
(2014)
J Immunother
, vol.37
, Issue.1
, pp. 26-35
-
-
Correale, P.1
Botta, C.2
Rotundo, M.S.3
Guglielmo, A.4
Conca, R.5
Licchetta, A.6
Pastina, P.7
Bestoso, E.8
Ciliberto, D.9
Cusi, M.G.10
Fioravanti, A.11
Guidelli, G.M.12
Bianco, M.T.13
Misso, G.14
Martino, E.15
Caraglia, M.16
Tassone, P.17
Mini, E.18
Mantovani, G.19
Ridolfi, R.20
Pirtoli, L.21
Tagliaferri, P.22
more..
-
41
-
-
84860798836
-
The regulation of the development and function of dendritic cell subsets by GM-CSF: more than a hematopoietic growth factor
-
COI: 1:CAS:528:DC%2BC38XnsFOqsbg%3D, PID: 22580403
-
Zhan Y, Xu Y, Lew AM (2012) The regulation of the development and function of dendritic cell subsets by GM-CSF: more than a hematopoietic growth factor. Mol Immunol 52(1):30–37. doi:10.1016/j.molimm.2012.04.009
-
(2012)
Mol Immunol
, vol.52
, Issue.1
, pp. 30-37
-
-
Zhan, Y.1
Xu, Y.2
Lew, A.M.3
-
42
-
-
84915817439
-
Myeloid-derived suppressor cells in multiple myeloma: pre-clinical research and translational opportunities
-
PID: 25538892
-
Botta C, Gulla A, Correale P, Tagliaferri P, Tassone P (2014) Myeloid-derived suppressor cells in multiple myeloma: pre-clinical research and translational opportunities. Front Oncol 4:348. doi:10.3389/fonc.2014.00348
-
(2014)
Front Oncol
, vol.4
, pp. 348
-
-
Botta, C.1
Gulla, A.2
Correale, P.3
Tagliaferri, P.4
Tassone, P.5
-
43
-
-
70249100293
-
Heterogeneity of CD4+ memory T cells: functional modules for tailored immunity
-
COI: 1:CAS:528:DC%2BD1MXhtVWrsrzJ, PID: 19672903
-
Sallusto F, Lanzavecchia A (2009) Heterogeneity of CD4+ memory T cells: functional modules for tailored immunity. Eur J Immunol 39(8):2076–2082. doi:10.1002/eji.200939722
-
(2009)
Eur J Immunol
, vol.39
, Issue.8
, pp. 2076-2082
-
-
Sallusto, F.1
Lanzavecchia, A.2
-
44
-
-
0033214348
-
CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs
-
COI: 1:CAS:528:DyaK1MXmsleqs7o%3D, PID: 10520991
-
Forster R, Schubel A, Breitfeld D, Kremmer E, Renner-Muller I, Wolf E, Lipp M (1999) CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs. Cell 99(1):23–33
-
(1999)
Cell
, vol.99
, Issue.1
, pp. 23-33
-
-
Forster, R.1
Schubel, A.2
Breitfeld, D.3
Kremmer, E.4
Renner-Muller, I.5
Wolf, E.6
Lipp, M.7
-
45
-
-
2142730100
-
Central memory and effector memory T cell subsets: function, generation, and maintenance
-
COI: 1:CAS:528:DC%2BD2cXktlOgsb8%3D, PID: 15032595
-
Sallusto F, Geginat J, Lanzavecchia A (2004) Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol 22:745–763. doi:10.1146/annurev.immunol.22.012703.104702
-
(2004)
Annu Rev Immunol
, vol.22
, pp. 745-763
-
-
Sallusto, F.1
Geginat, J.2
Lanzavecchia, A.3
-
46
-
-
84856545781
-
Tumor infiltration by T lymphocytes expressing chemokine receptor 7 (CCR7) is predictive of favorable outcome in patients with advanced colorectal carcinoma
-
PID: 22142823
-
Correale P, Rotundo MS, Botta C, Del Vecchio MT, Ginanneschi C, Licchetta A, Conca R, Apollinari S, De Luca F, Tassone P, Tagliaferri P (2012) Tumor infiltration by T lymphocytes expressing chemokine receptor 7 (CCR7) is predictive of favorable outcome in patients with advanced colorectal carcinoma. Clin Cancer Res 18(3):850–857. doi:10.1158/1078-0432.CCR-10-3186
-
(2012)
Clin Cancer Res
, vol.18
, Issue.3
, pp. 850-857
-
-
Correale, P.1
Rotundo, M.S.2
Botta, C.3
Del Vecchio, M.T.4
Ginanneschi, C.5
Licchetta, A.6
Conca, R.7
Apollinari, S.8
De Luca, F.9
Tassone, P.10
Tagliaferri, P.11
-
47
-
-
84879187714
-
Tumor infiltration by chemokine receptor 7 (CCR7)(+) T-lymphocytes is a favorable prognostic factor in metastatic colorectal cancer
-
PID: 22754775
-
Correale P, Rotundo MS, Botta C, Del Vecchio MT, Tassone P, Tagliaferri P (2012) Tumor infiltration by chemokine receptor 7 (CCR7)(+) T-lymphocytes is a favorable prognostic factor in metastatic colorectal cancer. Oncoimmunology 1(4):531–532
-
(2012)
Oncoimmunology
, vol.1
, Issue.4
, pp. 531-532
-
-
Correale, P.1
Rotundo, M.S.2
Botta, C.3
Del Vecchio, M.T.4
Tassone, P.5
Tagliaferri, P.6
-
48
-
-
43949105866
-
Regulatory T cells and immune tolerance
-
COI: 1:CAS:528:DC%2BD1cXntFaltrg%3D, PID: 18510923
-
Sakaguchi S, Yamaguchi T, Nomura T, Ono M (2008) Regulatory T cells and immune tolerance. Cell 133(5):775–787. doi:10.1016/j.cell.2008.05.009
-
(2008)
Cell
, vol.133
, Issue.5
, pp. 775-787
-
-
Sakaguchi, S.1
Yamaguchi, T.2
Nomura, T.3
Ono, M.4
|